西格列汀二甲双胍复合制剂治疗2型糖尿病的药物经济学评价 / Pharmacoeconomic evaluation of fixed-dose combination of sigliptin and metformin in the treatment of type 2 diabetes mellitus
目的 对西格列汀二甲双胍复合制剂(FDC)治疗 2 型糖尿病(T2DM)进行药物经济学评价.方法 以一项西格列汀二甲双胍FDC随机临床对照研究(RCT)的数据为基础,采用Tree Age pro2011 软件构建多状态的西格列汀二甲双胍FDC治疗T2DM的Markov模型,模拟在长期用药条件下西格列汀二甲双胍FDC治疗方案的经济性.以质量调整生命年(QALYs)为健康产出指标,以 3 倍的 2021 年国内生产总值(GDP)作为意愿支付阈值(WTP),用Markov模型模拟西格列汀二甲双胍 FDC 和单用二甲双胍治疗方案的长期效果与成本,并对相关参数进行敏感性分析,以检验结果的稳定性.结果 以1 年为1 个循环周期,模拟30 个周期后,西格列汀二甲双胍FDC组的增量成本-效用比(ICER)为 82 381.347 元/QALYs,小于意愿支付阈值(ICERObjective To make economic evaluation of the fixed-dose combination(FDC)of sigliptin and metformin in the treatment of type 2 diabetes mellitus(T2DM).Methods Based on the data from a randomized clini-cal controlled trial(RCT)of FDC of sigliptin and metformin,a multi-state Markov model of the FDC treatment for T2DM was constructed by using Tree Age pro 2011 software,and the economics of the treatment regimen of the FDC under long-term medication conditions was simulated.Using quality adjusted life years(QALYs)as a health output in-dicator,and three-time 2021 gross domestic product(GDP)as a willingness threshold to pay(WTP),the Markov models were used to simulate the long-term effects and costs of the treatment regimen of FDC and those of metformin alone,and the sensitivity analysis was performed on relevant parameters to test the stability of the results.Results Af-ter simulating a one-year cycle for 30 cycles,the incremental cost-effectiveness ratio(ICER)of FDC group was 82 381.347 yuan/QALYs,which was lower than the threshold of willingness to pay(ICER